New drug targets Cancer's genetic weakness in patients out of options
NCT ID NCT04962867
Summary
This trial is testing an experimental drug called E7090 for people with advanced or returning solid tumors that have specific changes in a gene called FGFR. It is for patients whose cancer has stopped responding to standard treatments or for whom no standard treatments are available. The main goal is to see if the drug can shrink or control the tumors and to understand its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hokkaido University Hospital
RECRUITINGKita-Ku, Sapporo, Hokkaido, 060-8648, Japan
Contact
-
Kanagawa Cancer Center
RECRUITINGYokohama, Kanagawa, 241-8515, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kyoto University Hospital
RECRUITINGSakyo-ku, Kyoto, 606-8507, Japan
Contact
-
Kyushu University Hospital
RECRUITINGHigashi-Ku, Fukuoka, 812-8582, Japan
Contact
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, Japan, 104-0045, Japan
Contact
-
Okayama University Hospital
RECRUITINGOkayama, 700-8558, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tohoku University Hospital
RECRUITINGAoba-ku, Sendai, Miyagi, 980-8574, Japan
Contact
Conditions
Explore the condition pages connected to this study.